Plurexa LLC
Seattle, WA
- UEI
- WAV2HG8VLNK4
- CAGE
- 9CEL5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 1209 6th Ave N #101, Seattle, WA 98109, USA
- Website
- plurexa.com
- Founded
- 2022
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Icahn School Of Medicine At Mount Sinai | U2CTR004867 | $258,550 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Mimetas US Inc. | Gaithersburg, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Xylyx Bio, Inc. | NY | — |
| Insphero, Inc. | Portland, ME | 325414 Biological Product (except Diagnostic) Manufacturing |
| Regennova, Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biopico Systems Inc. | Irvine, CA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
About the company
Plurexa LLC is a Seattle-based limited liability company registered in SAM.gov as a self-certified small disadvantaged business and for-profit organization. The company specializes in advanced biomedical research and development, focusing on innovative cellular and organoid technologies for medical research and drug development. While specific details about the company's founding and full scope of operations are not provided, the federal award history indicates Plurexa is deeply engaged in cutting-edge biomedical research, particularly in the realm of kidney disease and cellular engineering.
Plurexa LLC has secured federal grants primarily from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), focusing on groundbreaking research in polycystic kidney disease (PKD). Their primary grant work involves developing novel therapeutic approaches targeting myosin to treat PKD, including creating human kidney organoids that model disease progression and exploring potential drug development strategies. In a notable sub-award from the Icahn School of Medicine at Mount Sinai, Plurexa is developing microphysiological systems, specifically working to create reliable, self-renewing cellular sources for kidney research. This includes establishing distributable induced pluripotent stem (iPS) cells with various genetic backgrounds, developing kidney organoids, and creating kidney tubular epithelial cells for research and potential commercial distribution. Their work emphasizes creating validated cell lines with comprehensive characterization datasets, with the goal of supporting advanced medical research and potentially bringing microphysiological systems to market through distribution or fee-for-service models.
Quick answers
Is Plurexa LLC registered in SAM.gov?
Yes. Plurexa LLC's SAM.gov registration is active through March 25, 2027.
What is Plurexa LLC's most recent federal award?
Plurexa LLC's most recent federal grant award is Targeting myosin to treat polycystic kidney disease (R42DK136452), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on April 12, 2023.
On GovTribe
See Plurexa LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors